Introducing venetoclax, a powerful new drug that may treat CLL

Published on

Email this program

Get Link

Although venetoclax (formerly known as ABT-199), an investigational BCL-2 inhibitor, is a powerful drug for the treatment of patients with chronic lymphocytic leukaemia (CLL), it is associated with potentially fatal tumour lysis syndrome. At the 20th Congress of the European Hematology Association (EHA), Dr Barbara Eichhorst, of the University of Cologne, Cologne, Germany, explains that studies evaluating the optimal scheduling of venetoclax, suggest that it may have an important role in the treatment of patients with CLL, and more specifically, in patients who have relapsed or refractory CLL with a 17p deletion.

View more programs featuring

Page last updated on January 26, 2016